Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2004.02272.xPMID 15569112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Symptomatic Gastroesophageal Reflux in Acutely Hospitalized Patients

  2004cited by this paper
• Effect of PPI substitution on patient symptoms in a VA setting

  2003cited by this paper
• Esomeprazole 40 mg intravenous provides faster and more effective acid control than pantoprazole 40 mg intravenous after first dose and 5 days

  2003cited by this paper
• Esomeprazole 40 mg administered intravenously (IV) as a 3-minute injection or 30-minute infusion provides the same effective acid control in healthy subjects

  2003cited by this paper
• Esomeprazole 40 mg provides safe and effective healing of erosive esophagitis whether administered as an intravenous (IV) injection, an IV infusion or orally

  2003cited by this paper
• Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects

  2003cited by this paper
• Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides the same effective acid control as oral administration in healthy subjects

  2003cited by this paper
• Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

  2003cited by this paper
• The Effect of Intravenous Pantoprazole and Ranitidine for Improving Preoperative Gastric Fluid Properties in Adults Undergoing Elective Surgery

  2003cited by this paper
• Proton-Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients

  2002cited by this paper
• Effect of Esomeprazole 40 mg vs Omeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease

  2002cited by this paper
• Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD

  2001cited by this paper
• Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg following single dose administration

  2001cited by this paper
• Management of Severe Gastroesophageal Reflux Disease

  2001cited by this paper
• Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg

  2000cited by this paper
• Potential Uses of Intravenous Proton Pump Inhibitors to Control Gastric Acid Secretion

  2000cited by this paper
• Chemotherapy in the Treatment of Neuroendocrine Malignant Tumors

  2000cited by this paper
• Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori.

  2000cited by this paper
• Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.

  2000cited by this paper
• Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease

  2000cited by this paper
• The relationship between the control of pH and healing and symptom relief in gastro‐oesophageal reflux disease

  1995cited by this paper
• Is a fluoroscopic verification of the electrode position necessary in ambulatory intragastric pH monitoring?

  1992cited by this paper
• A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis.

  1991cited by this paper
• Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage.

  1978cited by this paper

• Premedication in pediatric Meckel scintigraphy: pantoprazole versus ranitidine for optimizing scan quality

  2025cites this paper
• Efficacy of Esomeprazole in NSAIDs Induced Gastric Ulcer: A Meta-Analysis

  2019influential citation
• Effects of pre- and postprandial aspirin on gastric bleeding based on clinical data and in vitro study

  2019cites this paper
• Gastritis and Peptic Ulcer Diseases in Dogs: A Review

  2018cites this paper
• Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression

  2016cites this paper
• Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease

  2014cites this paper
• A comparison of the acid‐inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism

  2012cites this paper
• Vergelijking van de zuurremmende effecten van esomeprazol en pantoprazol in relatie tot farmacokinetiek en CYP2C19-polymorfisme

  2012cites this paper
• Intravenous Proton Pump Inhibitors

  2012cites this paper
• Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.

  2011cites this paper
• Clinical effects of proton pump inhibitors: Focus on pharmacogenetics, kinetics and dynamics

  2010influential citation
• A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

  2010cites this paper
• Gastric Acid-Related Diseases: Focus on Esomeprazole

  2010cites this paper
• Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: A wireless pH metry analysis

  2010cites this paper
• Esomeprazole for the treatment of peptic ulcer bleeding

  2010cites this paper
• A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers

  2009cites this paper
• Pantoprazole intraveineux aux soins intensifs pédiatriques: un modèle de pharmacocinétique de population

  2009cites this paper
• Helicobacter pylori eradication: role of individual therapy constituents and therapy duration

  2009cites this paper
• Esomeprazole: a proton pump inhibitor

  2009cites this paper
• Intravenous esomeprazole for prevention of peptic ulcer re‐bleeding: rationale/design of Peptic Ulcer Bleed study

  2008cites this paper
• A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.

  2007cites this paper
• Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: An open, randomized crossover trial

  2007cites this paper
• Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults

  2007cites this paper
• Effect of Intravenous Esomeprazole 40 mg and Pantoprazole 40 mg on Intragastric pH in Healthy Subjects

  2007cites this paper
• Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.

  2007cites this paper
• Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults

  2007cites this paper
• Esomeprazole: a new proton pump inhibitor for NSAID-associated peptic ulcers and dyspepsia

  2006cites this paper
• Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.

  2006cites this paper
• Intravenous proton pump inhibitors.

  2006cites this paper
• Esomeprazole: potent acid suppression in the treatment of acid-related disorders

  2005cites this paper
• Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two‐way crossover study

  2005cites this paper
• Corrigendum

  2005cites this paper
• Intravenous Esomeprazole 40mg is Effective for the Control of Intragastric Acid Levels Whether Given as a 3-Minute Injection or a 30-Minute Infusion

  2005cites this paper
• Index

  2004cites this paper